contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


expres2ion-biotechnologies-scientific-article-published-about-the-phase-i-clinical-trial-of-the-covid-19-vaccine-abncov2

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics.

The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.

ExpreS2ion Biotech Holding

Hørsholm, Denmark, January 20, 2023 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that the journal The Lancet Microbe published an article...

<div class="abstract">Hørsholm, Denmark, January 20, 2023 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that the journal The Lancet Microbe published an article about the COVID-19 vaccine candidate ABNCoV2 titled "First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2" co-authored by ExpreS2ion scientists.</div>Abstract excerpt: "Immunisation with ABNCoV2 was well tolerated, safe, and resulted in a functional immune response. The data support the need for additional clinical development of ABNCoV2 as a second-generation SARS-CoV-2 vaccine. The modular cVLP platform will accelerate vaccine development, beyond SARS-CoV-2."This publication is a result of the close research collaboration in the COUGH-1 trial study group under the Prevent-nCoV consortium as announced in August 2021&nbsp;(<a href="https://news.cision.com/expres2ion-biotechnologies/r/positive-safety-and-efficacy-outcome-of-the-covid-19-clinical-phase-i-ii-study-for-the-abncov2-vacci,c3393447">https://news.cision.com/expres2ion-biotechnologies/r/positive-safety-and-efficacy-outcome-of-the-covid-19-clinical-phase-i-ii-study-for-the-abncov2-vacci,c3393447</a>) and November 2021&nbsp;(<a href="https://news.cision.com/expres2ion-biotechnologies/r/further-efficacy-data-from-the-covid-19-clinical-phase-i-ii-study-with-abncov2-confirms-strong-posit,c3451644">https://news.cision.com/expres2ion-biotechnologies/r/further-efficacy-data-from-the-covid-19-clinical-phase-i-ii-study-with-abncov2-confirms-strong-posit,c3451644</a>).The scientific article reference: Merel J Smit; Adam F Sander; Maud B P A Ariaans; Cyrielle Fougeroux; Constanze Heinzel; Rolf Fendel; Meral Esen; Peter G Kremsner; Rob ter Heine; Heiman F Wertheim; Manja Idorn; Søren Riis Paludan; Alexander P Underwood; Alekxander Binderup; Santseharay Ramirez; Jens Bukh; Max Soegaard; Sayit M Erdogan; Tobias Gustavsson; Stine Clemmensen; Thor G Theander; Ali Salanti; Mette Hamborg; Willem A de Jongh; Matthew B B McCall; Morten A Nielsen; Benjamin G Mordmüller; Robert Dagil; Louise Goksøyr; Thomas M Hulen; Christoph Janitzek; Daniel S Jensen; Sune Justesen; Paul K Khalifé; Andrea Kreidenweiss; Telma Lança; Olivia Lie-Andersen; Karina Teelen; Elena Vidal-Calvo. First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2. The Lancet Microbe. 2023 - <a href="https://doi.org/10.1016/S2666-5247(22)00337-8">https://doi.org/10.1016/S2666-5247(22)00337-8</a>. The article can also be found via this link&nbsp;(<a href="https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(22">https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(22</a>)00337-8/fulltext), as well as via the Research Publications&nbsp;(<a href="https://expres2ionbio.com/newspublications/research-publications/">https://expres2ionbio.com/newspublications/research-publications/</a>)&nbsp;page of ExpreS[2]ion's website. &nbsp;Certified Adviser Svensk Kapitalmarknadsgranskning AB

ExpreS2ion Biotechnologies: Scientific article published about the Phase I clinical trial of the COVID-19 vaccine ABNCoV2